Updated on 4 November 2013
It explained that the suit seeks to prevent Actavis from commercialising its abbreviated new drug application (ANDA) product prior to the expiration of its US patent.
In an analyst call earlier in November, Ranbaxy's CEO Arun Sawhneh had said, "Ranbaxy and Cipher intend to vigorously defend Absorica's intellectual property rights and pursue all available legal and regulatory pathways in defense of the product."
Ranbaxy had said in September that it has received a notice from Watson (Now Actavis) on its intent to bring to market a generic version of the acne drug. "Absorica was approved by the US FDA in May 2012 and was granted a three-year market exclusivity period, which expires in May 2015," Ranbaxy had said in a statement then.